(8), the MAGE-D4 core promoter region was located at promoter −358 bp to +172 bp, so we detected the methylation status of two areas (−111 bp to −32 bp and +29 bp to +112 bp) in the core promoter region in epigenetic drug-treated glioma cells. Here, MAGED4 is linked to central nervous system cancer.